Aprea Therapeutics
APRE
26 hedge funds and large institutions have $3.78M invested in Aprea Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
2.67% less ownership
Funds ownership: 38.19% → 35.51% (-2.7%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
45% less capital invested
Capital invested by funds: $6.83M → $3.78M (-$3.05M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$94.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.79K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.19K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.49K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exome Asset Management
New York
|
-$310K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$147K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$18.6K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$13.9K |
| 5 |
Morgan Stanley
New York
|
-$12.5K |
APRE Hedge Fund Activity: Q1 2025 in Review
26 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2025, worth a combined $3.78M — down 45% from $6.83M a quarter earlier.
Fund positioning in APRE was balanced in Q1 2025: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $94.2K. The largest seller was Exome Asset Management, cutting an estimated $310K.
- 26 institutional investors held Aprea Therapeutics (APRE) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $3.78M of Aprea Therapeutics stock for Q1 2025, down 45% quarter-over-quarter.
- 1 fund opened new Aprea Therapeutics positions in Q1 2025 and 1 closed out, a net change of 0 holders.
- The largest Aprea Therapeutics buyer in Q1 2025 was Citadel Advisors, an estimated $94.2K added.
- The largest Aprea Therapeutics seller in Q1 2025 was Exome Asset Management, an estimated $310K sold.
Based on aggregated 13F filings for Q1 2025.